加载中
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
前收盘价
US$0.2031
−US$0.0082 · -3.88%
盘后
US$0.2034
+US$0.0003 · +0.15%
10月12日 19:50 ET
盘中时间采用ET。市场数据可能有所延迟。
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
日内区间
当前US$0.2031
52周区间
当前US$0.2031
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
57
合理估值
情绪
51
多空交织
风险
73
高风险
动量
21
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
日内区间
当前US$0.2031
52周区间
当前US$0.2031
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 172.74万 USD | 123.35万 USD | 77.53万 USD | 30.64万 USD | 9万 USD |
| 毛利 | 172.74万 USD | 123.35万 USD | 77.53万 USD | 30.64万 USD | 9万 USD |
| 研究与开发 | 1008.13万 USD | 1440.65万 USD | 1955.15万 USD | 1533.3万 USD | 1302.24万 USD |
| 销售、一般及管理费用 | 1338.47万 USD | 1363.96万 USD | 1691.94万 USD | 1640.47万 USD | 1482.63万 USD |
| 营业费用 | 2294.94万 USD | 2825.85万 USD | 3676.3万 USD | 3208.65万 USD | 2842.31万 USD |
| 利息收入 | 600 USD | 9947 USD | 9.33万 USD | 12.53万 USD | 2734 USD |
| 利息支出 | 248.93万 USD | 34.04万 USD | 22.16万 USD | 17.31万 USD | 15.58万 USD |
| 折旧和摊销 | 121.64万 USD | 133.89万 USD | 141.33万 USD | 118.99万 USD | 114.52万 USD |
| 营业利润 | −2122.21万 USD | −2702.5万 USD | −3598.77万 USD | −3178.01万 USD | −2833.31万 USD |
| 净利润 | −2335.7万 USD | −2696.78万 USD | −3531.91万 USD | −3026.88万 USD | −2681.47万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年4月28日 | 1:20 | — | — |
已生效 2026年4月28日
1:20
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
